{
    "clinical_study": {
        "@rank": "84124", 
        "arm_group": [
            {
                "arm_group_label": "BG00012 treatment plus immunizations", 
                "arm_group_type": "Experimental", 
                "description": "Participants take BG00012 orally at a dose of 120 mg twice a day (BID) for the first 7 days and at a dose of 240 mg BID thereafter for up to 48 months. Participants will receive 0.5 ml of tetanus diphtheria toxoids (Td) and 0.5 ml of Pneumococcal Vaccine (Pneumovax 23) via intramuscular injection (IM) at week 24. Keyhole limpet hemocyanin (KLH) will be administered via subcutaneous injection at a dose of 1 mg at weeks 24, 26 and 28."
            }, 
            {
                "arm_group_label": "Immunizations alone", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants will receive 0.5 ml of tetanus diphtheria toxoids and 0.5 ml of Pneumococcal Vaccine via intramuscular injection (IM) on Day 1. KLH will be administered via subcutaneous injection at a dose of 1 mg on Day 1, and weeks 2 and 4."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the study is to evaluate the effects of BG00012 (Dimethyl Fumarate)\n      administered over approximately 6 months on immune responses to vaccination with tetanus\n      diphtheria toxoids vaccine (Td) [T cell-dependent anamnestic humoral response] and keyhole\n      limpet hemocyanian (KLH) [T cell-dependent neoantigen response] in subjects with relapsing\n      forms of multiple sclerosis (MS).\n\n      Secondary objectives are:  To evaluate the effects of BG00012 administered over\n      approximately 6 months on the immune response to vaccination with Pneumococcal Vaccine\n      (Pneumovax 23) [a mostly T cell-independent humoral response];  To evaluate the\n      pharmacodynamic effects of BG00012 on lymphocyte subtypes over 1 year of treatment;  To\n      evaluate the pharmacodynamic effect of BG00012 immunoglobulin levels over time and To\n      evaluate the safety and tolerability of BG00012"
        }, 
        "brief_title": "A Phase 3b Study of BG00012's Effect on Vaccination Response in Subjects With Relapsed Forms of Multiple Sclerosis", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsing Forms of Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Male and female subjects of childbearing potential must practice effective\n             contraception during the study and be willing and able to continue contraception for\n             30 days after their last dose of study treatment.\n\n          -  Must have a confirmed diagnosis of a relapsing form of multiple sclerosis (MS).\n\n          -  Must have a known history of tetanus immunization.\n\n        Key Exclusion Criteria:\n\n          -  Tetanus vaccination given less than 2 years or more than 15 years prior to screening,\n             or an anti-tetanus immunoglobulin G (IgG) titer at screening that is greater than\n             one-half the upper limit of detection for the assay.\n\n          -  Pneumococcal vaccination within the 5 years prior to screening.\n\n          -  Previous exposure to keyhole limpet hemocyanin (KLH) or vaccines containing KLH\n             components (e.g. cancer vaccines).\n\n          -  Known hypersensitivity to KLH, Pneumococcal Vaccine (Pneumovax 23), or\n             tetanus/diphtheria toxoids or any other administered vaccinations or their components\n             (e.g. thimerosol).\n\n          -  Known allergy to shellfish.\n\n          -  History of, or positive test result at screening for, hepatitis C virus (HCV)\n             antibody or hepatitis B virus or hepatitis B core antibody.\n\n          -  History of human immunodeficiency virus (HIV).\n\n        NOTE: Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097849", 
            "org_study_id": "109MS307"
        }, 
        "intervention": [
            {
                "arm_group_label": "BG00012 treatment plus immunizations", 
                "description": "Participants take BG00012 orally at a dose of 120 mg twice a day (BID) for the first 7 days and at a dose of 240 mg BID thereafter for up to 48 months. Capsules can be taken with or without food and each BG00012 capsule should be swallowed whole.", 
                "intervention_name": "BG00012 (Dimethyl Fumarate)", 
                "intervention_type": "Drug", 
                "other_name": "Tecfidera; Dimethyl Fumarate; DMF"
            }, 
            {
                "arm_group_label": [
                    "BG00012 treatment plus immunizations", 
                    "Immunizations alone"
                ], 
                "description": "Single intramuscular injection of 0.5ml", 
                "intervention_name": "Td (tetanus diphtheria toxoids)", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Td", 
                    "Tenivac"
                ]
            }, 
            {
                "arm_group_label": [
                    "BG00012 treatment plus immunizations", 
                    "Immunizations alone"
                ], 
                "description": "Single intramuscular injection of 0.5ml", 
                "intervention_name": "Pneumococcal Vaccine", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Pneumovax 23", 
                    "PPSV23"
                ]
            }, 
            {
                "arm_group_label": [
                    "BG00012 treatment plus immunizations", 
                    "Immunizations alone"
                ], 
                "description": "Three subcutaneous injections of 1 mg each.  Injections are given two weeks apart.", 
                "intervention_name": "KLH (Keyhole limpet hemocyanin)", 
                "intervention_type": "Biological", 
                "other_name": "Immucothel; KLH"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dimethyl fumarate", 
                "Keyhole-limpet hemocyanin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "tetanus diphtheria toxoids vaccine", 
            "Pneumovax 23", 
            "keyhole limpet hemocyanian", 
            "immune response"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gilbert", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85234"
                    }, 
                    "name": "Neurological Physicians of Arizona, Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33606"
                    }, 
                    "name": "Meridien Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40513"
                    }, 
                    "name": "Associates in Neurology, PSC"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Akron", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44302"
                    }, 
                    "name": "Neurology and Neuroscience Associates, Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73112"
                    }, 
                    "name": "Lynn Health Science Institute"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-Label Study to Assess the Effects of BG00012 on the Immune Response to Vaccination and on Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis", 
        "overall_contact": {
            "email": "clinicaltrials@biogenidec.com", 
            "last_name": "Biogen Idec Investigator"
        }, 
        "overall_official": {
            "affiliation": "Biogen Idec", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Proportion of Participants with a >=2-fold Rise in Anti-Tetanus Serum Immunoglobin G (IgG) Levels from Pre-Vaccination to 4 Weeks after Td Vaccination", 
                "safety_issue": "No", 
                "time_frame": "BG00012 treatment plus immunizations: Week 24, Week 28 Immunizations alone: Day 1 (baseline), Week 4"
            }, 
            {
                "measure": "Proportion of Participants with a >=2-fold Rise in Anti-KLH Serum IgG Levels from Pre-Vaccination to 4 Weeks After the Final KLH Vaccination", 
                "safety_issue": "No", 
                "time_frame": "BG00012 treatment plus immunizations: Week 24, Week 32 Immunizations alone: Day 1 (baseline), Week 8"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097849"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of Participants with a >=4-fold Rise in Anti-Tetanus Serum Immunoglobin G (IgG) Levels from Pre-Vaccination to 4 Weeks after Td Vaccination", 
                "safety_issue": "No", 
                "time_frame": "BG00012 treatment plus immunizations: Week 24, Week 28 Immunizations alone: Day 1 (baseline), Week 4"
            }, 
            {
                "measure": "Proportion of Participants with a >=4-fold Rise in Anti-KLH Serum IgG Levels from Pre-Vaccination to 4 Weeks After the Final KLH Vaccination", 
                "safety_issue": "No", 
                "time_frame": "BG00012 treatment plus immunizations: Week 24, Week 32 Immunizations alone: Day 1 (baseline), Week 8"
            }, 
            {
                "measure": "Proportion of Participants with a >=2- and a >=4-fold Rise in Anti-Pneumococcal IgG Levels from Pre-Vaccination to 4 Weeks After Pneumococcal Vaccine Vaccination", 
                "safety_issue": "No", 
                "time_frame": "BG00012 treatment plus immunizations: Week 24, Week 28 Immunizations alone: Day 1 (baseline), Week 4"
            }, 
            {
                "measure": "Anti-Tetanus Immunoglobulin Levels Over Time", 
                "safety_issue": "No", 
                "time_frame": "BG00012 treatment plus immunizations: Day -28 (screening), Weeks 24, 28, 32 Immunizations alone: Day -28 (screening), Day 1, Weeks 4, 8"
            }, 
            {
                "measure": "Anti-KLH Immunoglobulin Levels Over Time", 
                "safety_issue": "No", 
                "time_frame": "BG00012 treatment plus immunizations: Weeks 24, 28, 32, 36 Immunizations alone: Day 1, Weeks 4, 8, 12"
            }, 
            {
                "measure": "Anti-Pneumococcal Immunoglobulin Levels Over Time", 
                "safety_issue": "No", 
                "time_frame": "BG00012 treatment plus immunizations: Weeks 24, 28, 32 Immunizations alone: Day 1, Weeks 4, 8"
            }, 
            {
                "measure": "Change Over Time in Lymphocyte Subsets:  Total T cells, Total B cells, Total Natural Killer (NK)", 
                "safety_issue": "No", 
                "time_frame": "BG00012 treatment plus immunizations: Day 1 up to Week 52 Immunizations alone: Day 1 to Week 12"
            }, 
            {
                "measure": "Summary of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "BG00012 treatment plus immunizations: Day 1 up to Week 52 Immunizations alone:p: Day 1 to Week 12"
            }
        ], 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}